Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5674932 | 0.81 | MGAM (0.44) | GRIK1MGAMGAASIMGAM2 | |
| SCHEMBL10005848 | 0.81 | MGAM (0.44) | GRIK1MGAMGAASIMGAM2 | |
| Hydrochloric Acid SCHEMBL8106859 | 0.79 | MGAM (0.42) | GRIK1MGAMGAASIMGAM2 | |
| SCHEMBL28296858 | 0.78 | TSHR (0.31) | — | |
| SCHEMBL14388352 | 0.78 | GRIK1 (0.48) | GRIK1GRIK2SLC7A5 | |
| SCHEMBL291079 | 0.78 | — | — | |
| SCHEMBL14882533 | 0.78 | GRIK1 (0.48) | GRIK1GRIK2SLC7A5 | |
| SCHEMBL1078699 | 0.78 | — | — | |
| SCHEMBL2610089 | 0.77 | SLC1A1 (0.38) | GRIK1MGAMGAASIMGAM2 | |
| SCHEMBL12754580 | 0.76 | ALDH1A1 (0.35) | MGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101163-A1 | COMPOSITION FOR INHIBITING CANCER METASTASIS | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101163-A1 | COMPOSITION FOR INHIBITING CANCER METASTASIS | HDGF, MIF, HGF | GRIK1 1209/4885MGAM 3918/4885GAA 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.